Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study-Reference-Cited by-同舟云学术

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

Published:2012-02 Issue:3 Volume:48 Page:333-339
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Calvo E.,Escudier B.,Motzer R.J.,Oudard S.,Hutson T.E.,Porta C.,Bracarda S.,Grünwald V.,Thompson J.A.,Ravaud A.,Kim D.,Panneerselvam A.,Anak O.,Figlin R.A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Renal-cell carcinoma–molecular pathways and therapies;Brugarolas;N Engl J Med,2007

2. TSC2 regulates VEGF through mTOR-dependent and -independent pathways;Brugarolas;Cancer Cell,2003

3. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer;Thomas;Nat Med,2006

4. AFINITOR (everolimus) tablets for oral administration;Novartis Pharmaceuticals Corporation,2011

5. EAU guidelines on renal cell carcinoma: the 2010 update;Ljungberg;Eur Urol,2010

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update;Journal of Cancer Research and Clinical Oncology;2024-04-09

2. Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival;Cancers;2024-01-28

3. First reported double drug–drug interaction in a cancer renal patient under everolimus treatment: therapeutic drug monitoring and review of literature;European Journal of Medical Research;2023-06-29

4. ZDHHC2-Mediated AGK Palmitoylation Activates AKT–mTOR Signaling to Reduce Sunitinib Sensitivity in Renal Cell Carcinoma;Cancer Research;2023-04-20

5. Non-Interventional Management of Advanced Pancreatic Neuroendocrine Neoplasms in Patients with von Hippel-Lindau Disease;Cancers;2023-03-13